title: [Clinicopathological features and prognosis of primary appendiceal adenocarcinoma].
abstract: OBJECTIVE
  To explore the clinicopathological characteristics and prognostic factors of primary appendiceal adenocarcinoma.
  
  
  METHODS
  The clinicopathological data of 42 patients with primary appendiceal adenocarcinoma treated in the Cancer Hospital of Chinese Academy of Medical Sciences between March 1994 and October 2009 were retrospectively analyzed. The survival analysis was conducted using Kaplan-Meier method. The factors influencing survival were analyzed using univariate (Log-rank) and multivariate (Cox) models.
  
  
  RESULTS
  A total of 42 patients (29 female and 13 males, median age 56 years) with appendiceal adenocarcinoma were included in this study. Of them, 26 (61.9%) were mucinous adenocarcinoma, 12 (28.6%) were intestinal-type adenocarcinoma and 4 (9.5%) were signet cell carcinoma. 18 patients underwent curative resection, 20 patients received cytoreductive surgery, and 4 patients underwent biopsy only. Thirty patients received systemic chemotherapy (5-Fu-based regimens). One patient who died of postoperative pulmonary embolism on day 8 was excluded from the survival analysis. The overall 1-, 3-, and 5-year survival rate was 80.3%, 46.0% and 38.3%, respectively. Univariate analysis revealed that presence of symptoms of acute appendicitis, curative resection, histological grade, histological subtype, preoperative CEA level, systematic chemotherapy, and stage were all significant factors affecting the survival. Multivariate analysis showed that the preoperative CEA level (P = 0.01), histological grade (P = 0.001), and stage (P = 0.001) were independent prognostic factors.
  
  
  CONCLUSIONS
  High level of CEA, G2/3 grade, and advanced stage are associated with poor prognosis in patients with primary appendiceal adenocarcinoma.
authors.affiliation: Department of Abdominal Surgical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
authors.forename: Jian-wei
authors.initials: JW
authors.lastname: Liang
authors.forename: Zheng
authors.initials: Z
authors.lastname: Wang
authors.forename: Zhi-xiang
authors.initials: ZX
authors.lastname: Zhou
authors.forename: Xing-mao
authors.initials: XM
authors.lastname: Zhang
authors.forename: Jun-jie
authors.initials: JJ
authors.lastname: Hu
authors.forename: Ping
authors.initials: P
authors.lastname: Zhao
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001062:Appendectomy / Q000379:methods; D001063:Appendiceal Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D002272:Carcinoembryonic Antigen / Q000378:metabolism*; D018279:Carcinoma, Signet Ring Cell / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult
chemical_list: D002272:Carcinoembryonic Antigen; D005472:Fluorouracil